Amanda Lever, BSc; Auralyn MacKenzie, BSc; Larry Blandford, PharmD—Column Editor

With the arrival of clinically validated software technologies designed to treat disease, or “digital medicines,” comes a plethora of uncertainties related to how stakeholders will value these products relative to traditional medicines and how they will fit into today’s health care system.